2024 CDC Blood Donor Cohort Grant: Monitoring Respiratory Virus Trends and Immunologic Response Nationwide
The “Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort)” grant, provided by the Centers for Disease Control and Prevention (CDC), is suitable for organizations interested in establishing and sustaining a national longitudinal cohort of repeat blood donors. This cohort will monitor changes in antibody titers against respiratory viruses, assess risk factors for infection, vaccination status, respiratory symptoms, and immune response, and establish a repository for further analysis. Eligible applicants include Native American tribal governments, for-profit organizations, public and private educational institutions, nonprofits, and various levels of government entities with an interest in public health research and surveillance of respiratory viruses.
General Information
| Document Type: | Grants Notice |
| Opportunity Number: | RFA-IP-24-046 |
| Opportunity Title: | Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | |
| Expected Number of Awards: | 1 |
| CFDA Number(s): | 93.083 — Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases |
| Cost Sharing or Matching Requirement: | No |
| Version: | Forecast 1 |
| Forecasted Date: | Oct 03, 2023 |
| Last Updated Date: | Oct 03, 2023 |
| Estimated Post Date: | Nov 24, 2023 |
| Estimated Application Due Date: | Jan 23, 2024 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Estimated Award Date: | Aug 31, 2024 |
| Estimated Project Start Date: | Sep 01, 2024 |
| Fiscal Year: | 2024 |
| Archive Date: | Feb 22, 2024 |
| Estimated Total Program Funding: | $ 26,500,000 |
| Award Ceiling: | $ 4,500,000 |
| Award Floor: | $ 3,000,000 |
Eligibility
| Eligible Applicants: | Special district governments City or township governments State governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts County governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This project would establish and sustain a national longitudinal cohort of repeat blood donors with the purpose of monitoring changes in antibody titers against common or novel respiratory viruses; surveying the donors to assess for risk factors for infection, vaccination status, respiratory symptoms, and severe illness; and establishing a repository for further analysis as new assays to measure the immune response to respiratory virus infections are developed.During the COVID-19 pandemic, CDC used a contract mechanism to fund national serosurveillance studies, which used regular antibody assessments and surveys to monitor the burden of infection, risk factors for infection, and explore the duration and extend of immunity by population throughout the US (2020-2022). By 2022, algorithms for using quantitative antibody titers to detect reinfection were established and tested, creating novel systems for monitoring burden even in the setting of high overall seroprevalence.Adapting these tools to the current context, this research cooperative agreement would establish a large-scale longitudinal cohort (>50,000 persons) of repeat blood donors with the purpose of: 1) estimating the national burden of incident SARS-CoV-2 infection, and further adapting the approach to other respiratory viruses as technology allows including Respiratory Syncytial Virus, Influenza, Human Metapneumovirus, EVD-68, and others; 2) determining antibody thresholds for protection across multiple respiratory viruses; 3) assessing state- or region-specific population-level immunity to/risk for infection through tracking median antibody titers within various populations; and 4) monitoring waning immunity and changes in immune capabilities in the context of ongoing viral evolution. |
| Link to Additional Information: | |
| Grantor Contact Information: |
Dr. Amy Yang
404-718-8836
|